Sulphasalazine was initially used more than 50 yr ago to treat inflamm
atory arthritis but fell into disuse, only to be revived 25 yr ago for
rheumatoid arthritis. Since then its place as a second-line agent has
been established and its toxicity profile has been outlined. Subseque
ntly, its use has been widened to include other inflammatory rheumatic
diseases, with strong suggestions that it may be useful for several i
ndications. The history of its initial use, its reintroduction and the
establishment of its place in modern rheumatology are reviewed.